Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NIMH St. John's wort study RFP outlines eight-week trial for "major depressive disorder".

This article was originally published in The Tan Sheet

Executive Summary

ST. JOHN's WORT DEPRESSION ACUTE TREATMENT STUDY will compare the safety and clinical efficacy of eight weeks of daily treatment with 900 mg standardized Hypericum perforatum, or St. John's wort, a botanical dietary supplement commonly used as an antidepressant, to placebo in patients found to suffer from a major depressive disorder. The three-arm trial, sponsored by the National Institute of Mental Health, will include an examination in the third arm of patients receiving eight weeks of treatment with a prescription selective serotonin re-uptake inhibitor (SSRI) antidepressant "to document the sensitivity of the trial," NIMH said. However, "this trial will not have sufficient power to compare SSRI to Hypericum," the study protocol states.

You may also be interested in...



Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

People In Brief

Perrigo promotes in pricing, planning

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

UsernamePublicRestriction

Register

ID1135947

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel